Delivery Order SPE2DR25D3019-SPE2DR26FK4GL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,160.06 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count supply) on January 12, 2026, with an ultimate completion date of January 13, 2026. This non-set-aside, competitively awarded contract utilized firm fixed-price pricing and is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $25,475.56 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on January 14, 2026, with an ultimate completion date of January 15, 2026. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,720.85 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price, non-set-aside delivery order is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (formerly operating as AmerisourceBergen), is...
- The Defense Logistics Agency awarded a $39,246.38 delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a firm fixed price structure and an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract was issued on August 1, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $47,448.98 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on January 13, 2026, with an ultimate completion date of January 14, 2026. This firm fixed-price contract was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc., a...
- The Defense Logistics Agency awarded a delivery order valued at $4,434.02 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 28, 2025, with completion anticipated by August 29, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across military...
- The Defense Logistics Agency awarded a delivery order valued at $5,224.28 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count) on January 12, 2026, with an ultimate completion date of January 13, 2026. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $40,124.33 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of September 16, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor that supplies medications and medical supplies to military and veteran healthcare systems. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a ceiling value of $5,821.67 under a firm fixed price contract type. The award was made on December 12, 2025, with an ultimate completion date of December 15, 2025. This non-competitive delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion global pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a $3,710.89 delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for the supply of Gemtesa 75 mg tablets (90-count units). This non-set-aside, competitively awarded contract carries a firm fixed-price structure with an ultimate completion date of January 9, 2026, and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- SPE2DR25D3019Indefinite Delivery Contract
- SPE2DR25D3019-SPE2DR26FK4GLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,456.52 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on January 14, 2026, with completion scheduled for January 15, 2026. This firm fixed-price, non-set-aside contract is performed at the awardee's corporate office in Conshohocken, Pennsylvania. The delivery order operates under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies prescription medications, generic drugs, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to military treatment facilities and veterans' healthcare programs. This contract award reflects the company's ongoing role in fulfilling DLA's pharmaceutical supply needs through open competition, demonstrating its capability to meet federal procurement requirements for essential medications required by Department of Defense healthcare systems and other government medical institutions worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 1/13/26 |